On 8 November 2026, GlycoNex announced that a marketing authorisation application for SPD8, biosimilar to Amgen’s Prolia® (denosumab) was submitted to Japan’s Pharmaceuticals and Medical Devices Agency (PDMA).
SPD8 was co-developed by GlycoNex with Mitsubishi Gas Chemical. GlycoNex retains sales, distribution and commercialisation rights to SPD8 in all markets outside Japan and is actively seeking commercialisation partners in these markets.
The submission of the application follows GlycoNex’s June 2026 announcement that SPD8 met the primary endpoint in a Phase 3 osteoporosis study conducted in Japan, demonstrating therapeutic equivalence to Prolia®.
According to GlycoNex, SPD8 could receive regulatory approval in Japan at the end of 2027. GlycoNex is also preparing for a regulatory submission for SPD8 in Taiwan.
There is one approved denosumab biosimilar in Japan to date, Alvotech/Fuji Pharma’s AVT03 (DENOSUMAB BS 120 mg/1.4 mL in a vial for subcutaneous injection; September 2025), biosimilar to Daiichi Sankyo’s Ranmark® (marketed in other countries as Amgen’s Xgeva®). On 30 October 2026, China-headquartered Boan Biotech announced that it has licensed BA6101 (denosumab), biosimilar to Amgen’s Prolia®, to an undisclosed partner for Japan.
